Clopidogrel resistance marks recurrent risks.
SoRelle
Ruth
R
D000368:Aged; D015706:Bibliometrics; D002309:Cardiology; D000077144:Clopidogrel; D015331:Cohort Studies; D023903:Coronary Restenosis / Q000139:chemically induced; D004351:Drug Resistance; D047628:Estrogen Receptor alpha / Q000235:genetics; D005260:Female; D005492:Folic Acid / Q000009:adverse effects; D020022:Genetic Predisposition to Disease; D006331:Heart Diseases / Q000097:blood; D006801:Humans; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000517:prevention & control; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011237:Predictive Value of Tests; D012008:Recurrence; D012306:Risk; D015607:Stents; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D014805:Vitamin B 12 / Q000009:adverse effects; D025101:Vitamin B 6 / Q000009:adverse effects
D047628:Estrogen Receptor alpha; D010975:Platelet Aggregation Inhibitors; D020097:Natriuretic Peptide, Brain; D025101:Vitamin B 6; D005492:Folic Acid; D000077144:Clopidogrel; D013988:Ticlopidine; D014805:Vitamin B 12